BMY-14802 hydrochloride (BMY-14802-1) is a selective and orally activesigma receptorantagonist with anIC₅₀of 112 nM. BMY-14802 hydrochloride is also a5-HT1Aandadrenergic α1 receptorsagonist. BMY-14802 hydrochloride has antipsychotic effects^[1][2][3].

Similar to other 5-HT1A agonists, BMY-14802 hydrochloride affects the firing of 5-HTergic and catecholaminergic neurons and affects behaviors mediated by 5-HT in a 5-HT1A-sensitive manner. BMY-14802 hydrochloride is devoid of significant affinity for the D2 receptor^[3].

BMY-14802 (5 mg/kg, 10 mg/kg or 20 mg/kg, ip; once) hydrochloride shows anti-dyskinetic efficacy across a 4-fold dose range against L-DOPA-induced dyskinesias (LID) and is also effective in reducing D1 and D2 receptor agonist-induced dyskinesias. Importantly, at anti-LID doses, BMY-14802 hydrochloride does not affect the efficacy of L-DOPA against lesion-induced akinesia^[2].

384.85

C₁₈H₂₃ClF₂N₄O

105565-55-7

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.